BioWorld Asia

Feb. 19, 2003

Oxford GlycoSciences Considers Interest From Celltech, Others

LONDON - Celltech Group plc has refused to comment on reports that it is preparing to make a cash bid for Oxford GlycoSciences plc, undermining the agreed-to all-share takeover offer made by Cambridge Antibody Technology Group plc on Jan. 23. (BioWorld International) Read More

Diatos Raises EUR6.5M Privately To Fund Delivery Technology

Work On Lymphocyte Infection Could Have Implications In HIV

Dolly The Cloned Sheep Opened Research Doors In Biotechnology

Biotech Companies Included In New German Stock Index

SIRTeX Officials Welcome Idea Of $161M Acquisition By Cephalon

Active Biotech Seeks $26.5M In Discounted Rights Offering

Investment Rules Delay First Closing Of New Nordic Fund

Wilex Expands uPA Program Through Deal With San Raffaele

Fees For EMEA Registration Increasing For The First Time

Cerep, Sanofi-Synthélabo Renew Drug Discovery Collaboration

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for July 27, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...